NCT02973386View on ClinicalTrials.gov

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2025

Conditions
Local Advanced High Risk Nasopharyngeal Carcinoma
Interventions
DRUG

IMRT combine with cisplatin concurrent chemotherapy

Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.

DRUG

IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy

Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.

Trial Locations (1)

Unknown

Cancer Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02973386 - Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients | Biotech Hunter | Biotech Hunter